Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Common Equity (2016 - 2025)

OptimizeRx (OPRX) has disclosed Common Equity for 16 consecutive years, with $128.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 9.65% to $128.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $128.3 million through Dec 2025, up 9.65% year-over-year, with the annual reading at $128.3 million for FY2025, 9.65% up from the prior year.
  • Common Equity hit $128.3 million in Q4 2025 for OptimizeRx, up from $122.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $140.8 million in Q2 2022 to a low of $114.5 million in Q3 2024.
  • Historically, Common Equity has averaged $123.8 million across 5 years, with a median of $123.3 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 186.59% in 2021 and later decreased 17.76% in 2023.
  • Year by year, Common Equity stood at $131.4 million in 2021, then fell by 4.01% to $126.1 million in 2022, then rose by 0.35% to $126.6 million in 2023, then dropped by 7.55% to $117.0 million in 2024, then rose by 9.65% to $128.3 million in 2025.
  • Business Quant data shows Common Equity for OPRX at $128.3 million in Q4 2025, $122.3 million in Q3 2025, and $119.3 million in Q2 2025.